UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” to continue to benefit from the high demand for GLP-1 medications in the near-term, and while the CagriSema Phase 3 data in obesity was disappointing, it is still a higher efficacy treatment that could still show differentiation in type 2 diabetes. UBS is a buyer of weakness and says shares are at an attractive entry point following the “overdone” selloff.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk Poised for Short-Term Gains, while Eli Lilly Promises Stronger Long-Term Growth
- Novo Nordisk upgraded to Market Perform at Bernstein on valuation
- Novo Nordisk price target lowered to DKK 725 from DKK 975 at Berenberg
- Novo Nordisk upgraded to Market Perform from Underperform at Bernstein
- The UK Approves Amgen’s (AMGN) Tarlatamab to Treat Small Cell Lung Cancer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
